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Abstract 
Background: Antipsychotic drugs can cause hyperprolactinemia. However, 
hyperprolactinemia was also observed in treatment-naive patients with a first schizophrenic 
episode. This phenomenon might be related to the role of prolactin as a cytokine in autoimmune 
diseases. Extrapituitary prolactin production is regulated by an alternative promoter, which 
contains the functional single nucleotide polymorphism –1149 G/T (rs1341239). We examined 
whether this polymorphism was associated with hyperprolactinemia in patients with 
schizophrenia. 
Method: We recruited 443 patients with schizophrenia and 126 healthy controls. The 
functional polymorphism –1149 G/T (rs1341239) in the prolactin gene was genotyped with 
multiplexed primer extension, combined with MALDI-TOF mass spectrometry. Genotype and 
allele frequencies were compared between groups with the χ2 test and logistic regression models 
adjusting for covariates. 
Results: The frequency of genotypes and alleles in patients with schizophrenia did not 
differ from those in control subjects. A comparison between patients with schizophrenia with 
and without hyperprolactinemia revealed significantly higher frequency of the G allele in 
patients with hyperprolactinemia than in patients without it (χ2=7.25; p=0.007; OR = 1.44 [1.10 – 
1.89]). Accordingly, patients with hyperprolactinemia carried the GG genotype more frequently 
than patients without hyperprolactinemia (χ2=9.49; p=0.009). This association remained 
significant after adjusting the estimates for such covariates as sex, age, duration of the diseases 
and the dose of chlorpromazine equivalents. 
Conclusion: This study revealed a significant association between the polymorphic 
variant rs1341239 and the development of hyperprolactinemia in patients with schizophrenia. 
The serum prolactin concentration in patients with schizophrenia treated with antipsychotics may 
provide an indication of the activity of the gene that regulates extrapituitary prolactin production 
which is believed to play a role in the immune system. 
Key words: Cytokines; Hyperprolactinemia; Prolactin; PRL; –1149 G/T polymorphism; 
Schizophrenia 
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1. Introduction 
Long-term antipsychotic drug use remains the mainstay of treatment for patients with 
schizophrenia. However, pharmacotherapy with these drugs is complicated by several 
troublesome side effects, including metabolic, endocrine, cardiovascular, and movement 
disorders (Lally and MacCabe, 2015; Staller, 2006). One of these side effects may be 
hyperprolactinemia (Ajmal et al., 2014; Peuskens et al., 2014). Prolactin secretion is persistently 
inhibited by dopamine (Fitzgerald and Dinan, 2008; Peuskens et al., 2014), and antipsychotic 
drugs are believed to increase prolactin release by blocking dopamine receptors.  
Prolactin, also called the lactotrophin hormone, is a 199 amino-acid hormone synthesized 
and secreted in a pulsatile manner (~10 peaks per day in young adults) by the lactotroph cells of 
the anterior lobe of the pituitary gland (i.e., the adenohypophysis) (Fitzgerald and Dinan, 2008; 
Peuskens et al., 2014). The gene that encodes prolactin (PRL) has been mapped to chromosome 
6p21 (Evans, 1989; Owerbach et al., 1981). The 6p21 region has been identified as a 
susceptibility locus that harbors genes associated with schizophrenia (Roig et al., 2007; Schwab 
et al., 2003; Tochigi et al., 2004). A recent genome-wide analysis (Stefansson et al., 2009) also 
found that this region was significantly associated with schizophrenia. In humans, the PRL locus 
consists of a single gene that contains five coding exons, which is controlled by a pituitary-
specific promoter, and a non-coding exon, which is controlled by an alternative promoter. The 
latter promoter drives expression in non-pituitary tissues (Featherstone et al., 2012). Thus, apart 
from its role as a pituitary hormone, prolactin is also produced as a cytokine by immune cells; its 
receptor belongs to the family of cytokine receptors type 1 (Peeva et al., 2003). Stevens and 
colleagues (2001) identified a functional polymorphism in the PRL gene, –1149 G/T 
(rs1341239). They showed that the G allele was associated with increased extrapituitary 
promoter activity and increased levels of lymphocyte prolactin mRNA. This polymorphism was 
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previously associated with autoimmune diseases, such as systemic sclerosis (Fojtiková et al., 
2010), rheumatoid arthritis (Lee et al., 2015;  Reyes-Castillo et al, 2013), and systemic lupus 
erythematosus (SLE) (Lee et al., 2015; Stevens et al., 2001; Treadwell et al. 2015).  
The immune system is believed to be involved in the pathogenesis of schizophrenia 
(DeLisi and Crow, 1986; Leboyer et al., 2016). Indeed, SLE was positively associated with 
schizophrenia (Tiosano et al., 2016). Moreover, stress is an important activator of the immune 
response (Leonard, 2006), and psychosocial stress has been shown to trigger the outbreak of 
psychotic symptoms and activate prolactin secretion (Riecher-Rössler et al., 2013). Additionally, 
Rybakowski et al. (2012) found that the 1149G allele was associated with schizophrenia, and 
others showed that the 1149TT genotype was correlated with high levels of serum prolactin 
(Treadwell et al., 2015).  
In a collaborative Tomsk-Groningen research project, we measured serum prolactin 
levels (among other things) in patients with schizophrenia treated with antipsychotic drugs 
(Ivanova et al., 2016). In the present study, we investigated the possible role of the prolactin 
gene polymorphic variant, rs1341239, in the development of hyperprolactinemia in patients with 
schizophrenia.  
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2. Subjects and Methods 
 
2.1. Patients 
This study was carried out in accordance with the Code of Ethics of the World Medical 
Association (Declaration of Helsinki 1975, revised in Fortaleza, Brazil, 2013), established for 
experiments involving humans. We recruited patients from three psychiatric hospitals located in 
the Tomsk, Kemerovo, and Chita oblasts (regions) of Siberia, Russia. Each patient provided 
written informed consent, after the study was approved (protocol N63/7.2014) by the Local 
Bioethics Committee of the Mental Health Research Institute. None of the participants was 
compromised in their capacity/ability to consent; thus, consent from the next-of-kin was not 
necessary, and it was not recommended by the local ethics committee. The inclusion criteria 
were a clinical diagnosis of schizophrenia, according to the International Statistical 
Classification of Diseases and Related Health Problems, 10th Revision (ICD-10: F20), and age 
18-75 years old. Exclusion criteria were non-Caucasian physical appearance (e.g., Mongoloid, 
Buryats, or Khakassians); pregnancy, or any relevant gynecological or endocrine (thyroid) 
disorder; relevant pharmacological withdrawal symptoms; or organic brain disorders (e.g., 
epilepsy, Parkinson’s disease). A total of 191 patients were treated with conventional 
antipsychotics in oral and/or long-acting formulations. The most common conventional 
antipsychotic was haloperidol, which was used in 110 patients, but other treatments included oral 
chlorpromazine (CPZ), chlorprothixene, trifluoperazin and zuclopenthixol, and/or long-acting 
formulations of haloperidol-, zuclopenthixol- and flupenthixol-decanoate. A total of 176 patients 
were treated with atypical antipsychotics: risperidone, clozapine, quetiapine, olanzapine, 
amisulpride, paliperidone and sertindole. Different combinations of classical and atypical drugs 
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were used by 79 patients. To compare antipsychotic medications, all dosages were converted into 
CPZ equivalents (CPZeq, Andreasen et al., 2010). 
 
2.2. Control Group 
The control group consisted of 126 subjects (55 males/71 females), with a mean age of 38.5 ± 13.2 
years. These control subjects were recruited from a group of blood donors, hospital staff 
members, and students, on a voluntary basis. They were mentally and somatically healthy 
individuals.  
 
2.3. Blood sampling 
Blood samples were drawn after an 8-h overnight fast, into tubes containing EDTA, for DNA 
extraction, or into tubes with a clot activator (CAT) to isolate the serum (BD Vacutainer). Blood 
samples with EDTA were stored in several aliquots at -20 °C, until the DNA was isolated. Blood 
samples with CAT were centrifuged for 30 min at 2,000 g at 4 °C to isolate the serum; the 
serum was stored at -20 °C, until prolactin analysis. 
 
2.4. Hormone analysis 
The prolactin concentration was measured in serum with the AccuBind ELISA Microwell kit 
(Monobind Inc., USA). In this microplate immuno-enzymatic assay, the ELISA had a sensitivity 
of 0.004 ng/well. This was equivalent to a sample containing 0.150 ng/ml prolactin. Normal 
prolactin concentrations were defined as ≤20 ng/ml for men and ≤25 ng/ml for non-pregnant, 
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non-nursing women (Ivanova et al., 2016). These upper limits were consistent with criteria for 
hyperprolactinemia applied by Kelly et al. (2013) and Peuskens et al. (2014). 
 
2.4 Genotyping 
We performed the standard phenol-chloroform method to isolate DNA from leukocytes in whole 
peripheral blood drawn from patients with mental disorders. The DNA was genotyped for the 
studied gene in the Laboratory of Genetics of the University of Groningen with the 
MassARRAY® System (Agena Bioscience™). DNA concentrations were measured with a 
Thermo Scientific NanoDrop 8000 UV-Vis Spectrophotometer. 
 
2.5 Statistics 
Statistical analyses were performed with SPSS software for Windows, release 17. The Hardy-
Weinberg equilibrium of genotypic frequencies was tested using chi-square test. Chi-square test 
and the Fisher’s exact test, where necessary, were used for between-group comparisons of 
genotypes or allele frequencies. In addition, logistic regression models accounting for covariates 
were also estimated to test for association between the genetic polymorphism and 
hyperprolactinemia in patients with schizophrenia. Three genetic models were evaluated 
assuming additive, dominant or recessive effect of rare allele. The best model was chosen using 
Akaike Information Criteria (AIC). To address multiple testing issue, the significance of the 
models was estimated using Monte-Carlo permutations. Between-group differences in 
continuous variables were evaluated with the Student’s t-test or one-way analysis of variance 
(ANOVA). Comparisons of prolactin levels in different groups were performed with the 
Kruskal-Wallis test. P-values less than 0.05 were considered significant. 
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3. Results 
The total sample comprised 446 patients with schizophrenia (Table 1). Of these, 227 patients 
exhibited hyperprolactinemia (98 males/129 females), according to predefined criteria (Kelly et 
al. 2013; Peuskens et al. 2014).  
The prevalence of genotypes in both the schizophrenic and healthy groups was consistent with 
Hardy-Weinberg equilibrium. The frequency of genotypes and alleles in patients with 
schizophrenia did not differ from those in control subjects (Table 2). Table 3 shows the 
characteristics of patients with schizophrenia, and those with hyperprolactinemia are compared 
to those with normal prolactin levels.  
The frequency of the G allele of the polymorphic variant, rs1341239, was significantly higher in 
patients with hyperprolactinemia than in patients without it (Table 4; χ²=7.25; p=0.007; OR 1.44; 
95%Cl: 1.10 – 1.89). Accordingly, the GG genotype was found significantly more often in 
patients with hyperprolactinemia than in those without it (χ²=9.49; p=0.009; OR 1.86; 95%Cl: 
1.25 – 2.77). As this association can in part be explained by the effects of additional factors, such 
as sex, age, duration of disease, and the variation in the doses of antipsychotic drugs, we carried 
out a regression analysis using hyperprolactinemia as the dependent variable and the rs1341239 
genotypes as the fixed factor and sex, age, duration of disease, and chlorpromazine equivalents 
as covariates. The models assuming additive and dominant effects of the rare allele 
(rs1341239*T) were found statistically significant (OR = 0.698 [0.528-0.921], permutation p = 
0.012 and OR = 0.567 [0.373-0.856], permutation p = 0.008, respectively), and dominant model 
provided the best fit according to AIC (583.7 for dominant model vs 584.5 for additive model).  
However, the mean prolactin serum concentration was not significantly different among carriers 
of the GG (26.38 ng/ml; 95%CI: 14.21-57.03 ng/ml), GT (20.67; 95%CI: 12.5-47.00), and TT 
(22.41; 95%CI: 12.21-48.89) genotypes (Kruskal-Wallis test, p = 0.19; Table 2). 
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4. Discussion 
We studied the association between the –1149 G/T (rs1341239) variant of the PRL gene and 
antipsychotic drug-induced hyperprolactinemia in 443 white patients with schizophrenia from 
Siberia. We excluded patients with physiological or pathological conditions that might have 
affected prolactin secretion, and we corrected for variables related to prolactin secretion. The 
size of our reference group of healthy volunteers was limited; this limitation might explain the 
lack of significant differences between patients with schizophrenia and control subjects. 
However, the results presented in Table 2 revealed little difference between the groups; thus, it is 
unlikely that increasing the reference group would disclose significant differences. We studied 
both pre- and post-menopausal women with schizophrenia, and we used a fixed criterion for 
hyperprolactinemia. However, varying this criterion did not significantly alter the results in 
another study (Ivanova et al., 2016). All patients with schizophrenia had received long-term 
treatment with a variety of antipsychotic drugs. Therefore, another limitation of this study was 
the heterogeneity of antipsychotic drugs used and various length of treatment (see Ivanova et al., 
2016 for details). Moreover, the patients received different neuroleptic loads, due to the variable 
feeding and smoking habits, the use of concomitant drugs, and the poor brain penetration of 
some antipsychotic drugs that have a high affinity for P-glycoprotein (Moons et al., 2011). All 
these factors can distort the CPZeq dosage that reaches the pituitary gland, which lies outside the 
blood-brain-barrier. Moreover, other pharmacological receptor interactions (for example 5-
HT2C) may distort the relationship between CPZeq dosage and prolactin release (Ivanova et al., 
2016). Therefore, our results can only be considered preliminary.  
Our attention was drawn to a finding of the European First Episode Schizophrenia Trial 
(EUFEST), which showed that about 39% of the 74 patients (11/ 22 women and 18/52 men) with 
first schizophrenic episodes that were antipsychotic-naive exhibited hyperprolactinemia that 
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could not be explained by any reason except schizophrenia (Riecher-Rössler, et al., 2013). That 
finding corresponded to observations in other studies (González-Blanco et al., 2016), but 
contrasted with several other studies that found that drug-naïve patients with first episodes 
experienced spontaneous dyskinesia more frequently than healthy controls (Fenton, 2000; 
Tenback and Van Harten, 2011). Hyperprolactinemia is expected to be related to 
hypodopaminergic states (Fitzgerald and Dinan 2008; Peuskens et al. 2014) and dyskinesia is 
related to hyperdopaminergic states (Ivanova and Loonen, 2016; Loonen and Ivanova, 2013). In 
the present study, the patients chronically used antipsychotic drugs, which were potent 
dopamine-receptor blockers (Ivanova and Loonen, 2016). Therefore, differences in 
hyperprolactinemia prevalence could be attributed to differences in the activity of the prolactin 
gene (provided that the antipsychotic drugs randomly blocked pituitary dopamine receptors to a 
roughly similar extent in all groups). Extrapituitary prolactin is probably not an important 
contributor to prolactin serum levels. Accordingly, the -1149 G/T (rs1341239) variant of the PRL 
gene may contribute to a dopamine-independent release of prolactin from the pituitary gland. 
The results of this study differed from those of Treadwell et al. (2015), who found that the 
1149TT genotype was correlated with elevated serum prolactin levels. However, they studied 
patients with SLE that were not using dopamine receptor antagonists. Moreover, their results 
contrasted with data from the meta-analysis by Lee et al. (2015). 
Prolactin is active as a hormone and, probably, also as a cytokine (Peeva et al. 2003). This 
duality may explain the associations reported between 1149 G/T (rs1341239) variants and 
certain autoimmune diseases. When pituitary dopamine receptors are inactivated with 
antipsychotic drugs, prolactin release from the pituitary may be correlated with increased 
prolactin release from extrapituitary sources, like immune cells within the brain.  As a cytokine, 
the intracerebral release of prolactin may induce neuroplastic changes, which might explain the 
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relationship between 1149 G/T (rs1341239) variants and the pathogenesis of mental disorders, 
like schizophrenia (see above).  
In conclusion, this study showed that, among patients with schizophrenia, the G allele of the 
polymorphic variant, rs1341239, of the PRL gene was observed significantly more frequently in 
patients with hyperprolactinemia than in patients without it. Because extrapituitary prolactin is 
unlikely to be an important contributor to serum prolactin, the hyperprolactinemia is probably 
related to effects of the 1149 G/T (rs1341239) allele on pituitary prolactin release. Therefore, 
among patients with schizophrenia treated with antipsychotics, the serum concentration of 
prolactin may provide an indication of the activity of the gene that regulates extrapituitary 
prolactin release, which is believed to play a role in the immune system. 
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Table 1. Demographics and clinical characteristics of patients with schizophrenia 
  
Trait All (446) Male (221) Female (225) p -value* 
Age 
(mean ± SD) 
42.1±12.4 37.8 ± 11.9 45.2 ± 13.9 
p<0.0001 
Duration of disease, years 
Median (IQR) 
13 (6; 22) 11 (5; 18) 15 (7; 26) 
p<0.0001 
Daily dose of antipsychotics 
in CPZeq 
Median (IQR) 
425 (240; 750) 500 (300; 750) 372 (200; 750) 
p=0.003 
Prolactin ng/ml 
Median (IQR) 
23.32  
(13.12; 49.96) 
18.18  
(10.61; 32.47) 
34.89  
(15.50; 65.03) 
p<0.0001 
 
CPZeq: chlorpromazine equivalents; IQR: interquartile range; *calculated with either the t-test or 
the Mann-Whitney U test, as appropriate 
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Table 2. Frequencies of genotypes and alleles of the rs1341239 polymorphism in the PRL gene 
in patients with schizophrenia and controls  
Genotypes, 
Alleles 
Patients with 
schizophrenia 
n (%) 
Control 
n (%) 
OR 
χ2 p 
Estimate 95% CI 
GG 154 (34.8%) 50 (39.7%) 0.81 0.54 – 1.22 
1.694 0.429 GT 208 (47.0%) 51 (40.5%) 1.30 0.87 – 1.95 
TT 81 (18.3%) 25 (19.8%) 0.90 0.55 – 1.49 
G 516 (58.2%) 151 (59.9%) 0.93 0.70 – 1.24 
0.230 0.630 
T 370 (41.8%) 101 (40.1%) 1.07 0.81 – 1.43 
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Table 3. Demographics and clinical characteristics of patients with schizophrenia, with or 
without hyperprolactinemia (HP) 
 
Trait Without HP (n = 219) With HP (n = 227) p-value* 
Age (mean ± S.D.) 42.94± 13.56 40.19 ± 13.19 p=0.031 
Male/female 123/96 98/129 p=0.006 
Duration of disease, years 
Median (IQR) 
14.0 (8.0; 22.0) 11.0 (4.0; 22.0) 
p=0.041 
Daily dose of antipsychotics 
in CPZeq 
Median (IQR) 
400 (225; 750) 400 (280; 750) 
p=0.074 
Prolactin ng/ml 
Median (IQR) 
12.9 (8.14; 16.82) 49.66 (32.5; 76.27) 
p<0.001 
CPZeq: chlorpromazine equivalents; IQR: interquartile range; *calculated with either the t-test or 
the Mann-Whitney U test, as appropriate 
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Table 4. Frequency of genotypes and alleles of the rs1341239 polymorphism in the PRL 
gene, among patients with schizophrenia, with and without hyperprolactinemia (HP)   
 
Genotypes, 
Alleles 
With HP 
n (%) 
Without HP 
n (%) 
OR 
χ2 p 
Estimate 95% CI 
GG 94 (41.6%) 60 (27.6%) 1.86 1.25 – 2.77 
9.49 0.009 GT 95 (42.0%) 113 (52.1%) 0.67 0.46 – 0.97 
TT 37 (16.4%) 44 (20.3%) 0.77 0.47 – 1.25 
G 283 (62.6%) 233 (53.7%) 1.44 1.10 – 1.89 
7.25 0.007 
T 169 (37.4%) 201 (46.3%) 0.69 0.53 – 0.81 
 
 
 
